AR052174A1 - Sulfonamido - macrociclos y sus sales como inhibidoras de tie2, composicion farmaceutica que comprende estos compuestos, metodo de prepararlos y su uso - Google Patents
Sulfonamido - macrociclos y sus sales como inhibidoras de tie2, composicion farmaceutica que comprende estos compuestos, metodo de prepararlos y su usoInfo
- Publication number
- AR052174A1 AR052174A1 ARP050105398A ARP050105398A AR052174A1 AR 052174 A1 AR052174 A1 AR 052174A1 AR P050105398 A ARP050105398 A AR P050105398A AR P050105398 A ARP050105398 A AR P050105398A AR 052174 A1 AR052174 A1 AR 052174A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cor5
- phenylene
- oxy
- methylene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composicion farmacéutica para el tratamiento de enfermedades de crecimiento vascular desregulado o de enfermedades acompanadas por un crecimiento vascular desregulado, donde los compuestos interfieren en forma efectiva con la angiopoyetina y por lo tanto afectan la senalizacion de Tie2. Reivindicacion 1: un compuesto caracterizado porque responde a la formula general (1) en donde A es fenileno o C6-heteroarileno; Z se selecciona del grupo compuesto preferentemente por O, S, NR3 y CHR3; R1, R2 y R3 son iguales o diferentes y son en forma independiente entre sí seleccionados del grupo compuesto preferentemente por H y C1-10-alquilo, donde C1-10-alquilo es no sustituido o mono o polisustituido con hidroxi; R4 se seleccionan del grupo compuesto preferentemente por H, halogeno, nitro, amino, ciano, C1-6 alquilo, C1-6 alcoxi, -NH-C1-6 alquilo, -N(C1-6-alquilo)2, -(CH2)p-COR5, -(CH2)p-NHCOR5, -(CH2)p-NH-CO-NR5R6, -(CH2)p-NHS(O)2R5, -(CH2)p-CO-NR5R6 y -O-(CH2)p-COR5, X es un enlace o metileno; Y se selecciona del grupo compuesto preferentemente por metilendioxifenilo, etilendioxifenilo, -fenilen-D-NH-COR5, -fenilen-D-NH-CONR5R6, -fenilen-D-NH-S(O)2R5, -fenilen-D-O-(CH2)p-COR5, - fenilen-D-O-(CH2)p-R7, -N-(R5-G)-piperazin-N'- ilmetilo, -N-(R7-SO2-)-piperazin-N'-ilo, -oxi-C6-18-arilo, -oxi-C5-18-heteroarilo, - oxi-(CH2)n-NH-COR5, -oxi-(CH2)n-NH-CONR5R6, -oxi-(CH2)n-NH-S(O)2R5, -NH-(CH2)n-NH-COR5, -NH-(CH2)n-NH-CONR5R6, -NH-(CH2)n- NH-S(O)2R5 y -fenilen-NH-E-CONR5R6, donde fenileno es no sustituido o mono o polisustituido en forma independiente entre sí con hidroxi, halogeno, nitro, ciano, carboxi, amino, C1-6 alquilo, C1-6 alcoxi, -NH-C1-6 alquilo, -N(C1-6 alquilo)2, C1-6-halogenalquilo, C1-6- halogenalcoxi, C1-6 alquiltio y/o C1-6 alquilcarbonilo, y donde -oxi-C6-18 arilo y -oxi-C5-18-heteroarilo son no sustituidos o son mono- o polisustituidos en forma independiente entre sí con hidroxi, halogeno, nitro, ciano, carboxi, amino, C1-6 alquilo, C1-6 alcoxi, - NH-C1-6 alquilo, -N(C1-6-alquilo)2, -C1-6-haloalquilo, C1-6-haloalcoxi, c1-6-alquiltio, C1-6-alquilcarbonilo, -NH-S(O)2-R5, -NH-COR5, - NHCONR5R6, -O-(CH2)p-COR5 y/o -O-(CH2)p-R5; D es un enlace, metileno o etileno; E es -CR8R9-, donde R8 y R9 son iguales o diferentes y son en forma independiente entre sí seleccionados del grupo compuesto preferentemente por H y metilo; o R8 y R9 forman juntos una union de metileno de 3 a 10 miembros, en donde hasta dos grupos metileno opcionalmente se reemplazan con O, S y/o NR1; G es -SO2-, -CONH- o -C=O; R5 se selecciona del grupo compuesto preferentemente por H y residuos seleccionados del grupo que comprende C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C3-8 cicloalquilo, -(CH2)p-C6-11-arilo y -(CH2)p-C5-10-heteroarilo, donde dichos residuos son no sustituidos o son mono- o polisustituidos en forma independiente entre sí con hidroxi, halogeno, nitro, ciano, carboxi, amino, C1-6 alquilo, C1-6 alquenilo, C1-6 alquinilo, C1-6 alcoxi, -NH- C1-6 alquilo, N(C1-6 alquilo)2, C1-6-halogenalquilo, C1-6- halogenalcoxi, C1-6-alquiltio, -S(O)-C1-6 alquilo, -S(O)2-C1-6 alquilo, C1-6-alquilcarbonilo, fenilo, fenoxi y/o piridilo, y donde los átomos de C de la cadena principal de C de C3-8 cicloalquilo no se interrumpen o se interrumpen una o más veces por átomos de N, átomos de O, átomos de S y/o una o más porciones C=O y/o donde uno o más ligaduras dobles pueden estar incluidas en la cadena principal de C; o R5 y R6 forman juntos una union de metileno de 3 a 10 miembros, en donde hasta dos grupos metileno pueden reemplazarse con O, S y/o -NR1; R6 es H o c1-10 alquilo, o R5 y R6 forman juntos una union de metileno de 3 a 10 en donde hasta dos grupos metileno pueden reemplazarse con O, S y/o -NR1;R7 es C6-11 arilo o C5-10 heteroarilo, donde C6-11arilo o C5-10 heteroarilo con no sustituidos o son mono- o polisustituidos con hidroxi, halogeno, nitro, ciano, carboxi, amino, C1-6 alquilo, C1-6 alcoxi, -NH-C1-6 alquilo, N(C1-6alquilo)2, - C1-6 haloalquilo, C1-6-haloalcoxi, C1-6 alquiltio, -S(O)C1-6 alquilo, S(O)2-C1-6 alquilo, C1-6 alquilcarbonilo, fenilo, fenoxi y/o piridilo; m es entre 3 y 6; n es 2 o 3; p es entre 0 y 2; y solvatos, hidratos, N-oxidos, isomeros, diastereomeros, enantiomeros y sales de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04090508A EP1674469A1 (en) | 2004-12-22 | 2004-12-22 | Sulfonamido-macrocycles as Tie2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052174A1 true AR052174A1 (es) | 2007-03-07 |
Family
ID=34928852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105398A AR052174A1 (es) | 2004-12-22 | 2005-12-21 | Sulfonamido - macrociclos y sus sales como inhibidoras de tie2, composicion farmaceutica que comprende estos compuestos, metodo de prepararlos y su uso |
Country Status (16)
Country | Link |
---|---|
EP (2) | EP1674469A1 (es) |
JP (1) | JP2008524302A (es) |
KR (1) | KR20070097525A (es) |
CN (1) | CN101087797A (es) |
AR (1) | AR052174A1 (es) |
AU (1) | AU2005318360A1 (es) |
BR (1) | BRPI0519210A2 (es) |
CA (1) | CA2590522A1 (es) |
GT (1) | GT200500382A (es) |
IL (1) | IL183163A0 (es) |
NO (1) | NO20073836L (es) |
PA (1) | PA8658101A1 (es) |
PE (1) | PE20060869A1 (es) |
TW (1) | TW200637829A (es) |
UY (1) | UY29294A1 (es) |
WO (1) | WO2006066956A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1873159A1 (en) * | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
EP1870416A1 (en) * | 2006-06-21 | 2007-12-26 | Bayer Schering Pharma Aktiengesellschaft | Sulphonamido-macrocycles as tie2 inhibitors |
AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
ES2786552T3 (es) | 2015-09-29 | 2020-10-13 | Bayer Pharma AG | Compuestos de sulfondiimina macrocíclicos nuevos |
EP3359544B1 (en) * | 2015-10-08 | 2020-08-12 | Bayer Pharma Aktiengesellschaft | Novel modified macrocyclic compounds |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
EP3601236A1 (en) | 2017-03-28 | 2020-02-05 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
ES2900199T3 (es) | 2017-03-28 | 2022-03-16 | Bayer Ag | Novedosos compuestos macrocíclicos inhibidores de PTEFB |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003220970A1 (en) * | 2002-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
DE10239042A1 (de) * | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
-
2004
- 2004-12-22 EP EP04090508A patent/EP1674469A1/en not_active Withdrawn
-
2005
- 2005-12-19 CA CA002590522A patent/CA2590522A1/en not_active Abandoned
- 2005-12-19 CN CNA2005800442932A patent/CN101087797A/zh active Pending
- 2005-12-19 EP EP05826661A patent/EP1828209A2/en not_active Withdrawn
- 2005-12-19 AU AU2005318360A patent/AU2005318360A1/en not_active Abandoned
- 2005-12-19 BR BRPI0519210-2A patent/BRPI0519210A2/pt not_active Application Discontinuation
- 2005-12-19 JP JP2007547385A patent/JP2008524302A/ja active Pending
- 2005-12-19 WO PCT/EP2005/013956 patent/WO2006066956A2/en active Application Filing
- 2005-12-19 KR KR1020077016660A patent/KR20070097525A/ko not_active Application Discontinuation
- 2005-12-21 AR ARP050105398A patent/AR052174A1/es not_active Application Discontinuation
- 2005-12-21 UY UY29294A patent/UY29294A1/es not_active Application Discontinuation
- 2005-12-21 GT GT200500382A patent/GT200500382A/es unknown
- 2005-12-22 TW TW094146432A patent/TW200637829A/zh unknown
- 2005-12-22 PA PA20058658101A patent/PA8658101A1/es unknown
-
2006
- 2006-01-03 PE PE2006000012A patent/PE20060869A1/es not_active Application Discontinuation
-
2007
- 2007-05-14 IL IL183163A patent/IL183163A0/en unknown
- 2007-07-20 NO NO20073836A patent/NO20073836L/no unknown
Also Published As
Publication number | Publication date |
---|---|
NO20073836L (no) | 2007-09-21 |
EP1828209A2 (en) | 2007-09-05 |
AU2005318360A1 (en) | 2006-06-29 |
UY29294A1 (es) | 2006-07-31 |
PE20060869A1 (es) | 2006-10-01 |
PA8658101A1 (es) | 2006-09-22 |
WO2006066956A3 (en) | 2006-10-12 |
BRPI0519210A2 (pt) | 2009-01-06 |
GT200500382A (es) | 2006-08-01 |
EP1674469A1 (en) | 2006-06-28 |
CN101087797A (zh) | 2007-12-12 |
WO2006066956A2 (en) | 2006-06-29 |
KR20070097525A (ko) | 2007-10-04 |
CA2590522A1 (en) | 2006-06-29 |
JP2008524302A (ja) | 2008-07-10 |
IL183163A0 (en) | 2007-09-20 |
TW200637829A (en) | 2006-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR052174A1 (es) | Sulfonamido - macrociclos y sus sales como inhibidoras de tie2, composicion farmaceutica que comprende estos compuestos, metodo de prepararlos y su uso | |
AR116978A1 (es) | Fungicidas de tolilo sustituido | |
AR127309A2 (es) | Derivados de piridazinona | |
EA201791254A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
PE20171057A1 (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
AR062510A1 (es) | Derivados de piridona con actividad antagonista de mch y medicamentos que comprenden estos compuestos | |
AR077505A1 (es) | Compuestos de piridina y sus usos | |
AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
AR051921A1 (es) | Acidos sustituidos utiles como compuestos farmaceuticos para tratar trastornos respiratorios, composiciones farmaceuticas que los contienen, y procesos para su preparacion | |
AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR078786A1 (es) | Derivados de la cromenona | |
AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
ECSP088963A (es) | Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmacéuticas que las comprenden | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
PE20110405A1 (es) | Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion | |
AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
AR054725A1 (es) | Pirazolopiridinas y sales de las mismas, una composicion farmaceutica que comprende dichos compuestos, un metodo para prepararlos y su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |